ArTS Archivio della ricerca di Trieste

MACOR, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5011
EU - Europa 3384
AS - Asia 328
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 5
AF - Africa 4
SA - Sud America 4
Totale 8745
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4823
PL - Polonia 1528
SE - Svezia 480
IT - Italia 470
UA - Ucraina 245
DE - Germania 216
CA - Canada 188
CN - Cina 157
GB - Regno Unito 111
TR - Turchia 92
BG - Bulgaria 82
FI - Finlandia 71
IE - Irlanda 68
BE - Belgio 39
VN - Vietnam 36
FR - Francia 30
RU - Federazione Russa 16
IN - India 10
EU - Europa 7
IR - Iran 7
JP - Giappone 7
NL - Olanda 7
ES - Italia 6
AU - Australia 4
RO - Romania 4
TW - Taiwan 4
GR - Grecia 3
PT - Portogallo 3
SA - Arabia Saudita 3
TN - Tunisia 3
A1 - ???statistics.table.value.countryCode.A1??? 2
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
HU - Ungheria 2
MY - Malesia 2
PK - Pakistan 2
AR - Argentina 1
CO - Colombia 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EG - Egitto 1
ID - Indonesia 1
IL - Israele 1
KW - Kuwait 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PE - Perù 1
RS - Serbia 1
SG - Singapore 1
Totale 8745
Salva come PNG Salva come JPEG
Città #
Warsaw 1528
Woodbridge 644
Fairfield 616
Chandler 538
Ann Arbor 516
Houston 352
Wilmington 308
Ashburn 265
Jacksonville 253
Seattle 225
Trieste 218
Cambridge 192
Montréal 151
Mcallen 143
Princeton 138
Munich 131
Izmir 88
Sofia 81
Dublin 68
Beijing 50
Dearborn 46
Brussels 39
San Diego 38
Redmond 37
Dong Ket 35
Falls Church 31
Toronto 28
Redwood City 25
Des Moines 20
Boardman 19
Sacile 19
Düsseldorf 14
Hefei 14
Jinan 13
Milan 13
Phoenix 12
Nanjing 11
Buffalo 10
Chicago 10
Norwalk 10
Rome 8
Udine 8
Kunming 7
Bremen 6
Cascina 6
Centro 6
Detroit 6
Padova 6
San Mateo 6
Fuzhou 5
Hebei 5
Palermo 5
Amsterdam 4
Guangzhou 4
Latina 4
Monfalcone 4
Pradamano 4
Taizhou 4
Tianjin 4
Trivandrum 4
Verona 4
Zhengzhou 4
Barcelona 3
Clearwater 3
Fremont 3
Hangzhou 3
Helsinki 3
Indiana 3
Kaohsiung 3
Leawood 3
Madeirã 3
Montreal 3
Nanchang 3
North Bergen 3
Paris 3
Saint Louis 3
San Francisco 3
Shenyang 3
Thuwal 3
Venezia 3
Wuhan 3
Andover 2
Ardabil 2
Arzene 2
Augusta 2
Baotou 2
Changsha 2
Chengdu 2
Courtenay 2
East Lansing 2
Mestre 2
Mogliano Veneto 2
San Giórgio Di Nogaro 2
Scafati 2
Shanghai 2
Sheffield 2
Suzhou 2
Taiyuan 2
Taunsa 2
Tokyo 2
Totale 7158
Salva come PNG Salva come JPEG
Nome #
Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications 709
Meniscal ossicles as micro-CT imaging biomarker in a rodent model of antigen-induced arthritis: A synchrotron-based x-ray pilot study 329
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies 318
Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers 301
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation 291
Targeted delivery of neutralizing anti-C5 antibody to renal endothelium prevents complement- dependent tissue damage 288
Invasive meningococcal disease in three siblings with hereditary deficiency of the 8th component of complement: Evidence for the importance of an early diagnosis 278
Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia 239
New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats 228
A non-complement-fixing antibody to  2 glycoprotein I as a novel therapy for antiphospholipid syndrome 215
New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. 203
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. 193
Complement as a biological tool to control tumor growth 183
null 166
Targeted nanoparticles and complement activation 162
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. 161
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. 149
The seventh complement component is expressed on endothelial cells membrane and exerts an anti-inflammatory action 147
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59 142
An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. 138
Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery 135
Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5 130
Critical role and therapeutic control of the lectin pathway of complement activation in an abortion-prone mouse mating 130
A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles 129
Complement as effector system in cancer immunotherapy. 128
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy 126
Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. 118
Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma. 117
null 117
Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. 116
Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity. 110
Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. 109
Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. 106
null 105
Diagnostic and prognostic role of eEF1A in chronic lymphocytic leukaemia 104
Alterations in trabecular bone μ-architecture and cartilages in rats with antigen-induced arthritis (AIA) resulting from synchrotron-based X-ray imaging analysis 103
A Human Monoclonal Antibody Against Domain I Of beta 2-Glycoprotein I prevents Clotting and Fetal Loss Induced By Polyclonal Anti-Phospholipid Antibodies In Animal Models. 102
Complement C1q and C8beta deficiency in an individual with recurrent bacterial meningitis and adult-onset systemic lupus erythematosus-like illness. 100
Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. 100
Humoral immunotherapy of multiple myeloma: perspectives and perplexities. 99
Complement in human diseases: Lessons from complement deficiencies. 98
In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. 96
The development of atypical hemolytic uremic syndrome depends on complement C5. 91
Simple scale-up of recombinant antibody production using an UCOE containing vector 89
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 89
Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells 86
High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study 85
The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies 82
P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma. 82
Cubosomes for in vivo fluorescence lifetime imaging 80
DEVELOPMENT OF CHLORAMBUCIL/HYDROXYCHLOROQUINE-LOADED ANTI-CD20 NANOPARTICLES FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA : IN VITRO MODEL 78
OP0023 Targeted Polymeric Nanoparticles as Diagnostic and Therapeutic Tool for Rheumatoid Arthritis 78
Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis 74
The Inflammatory Feed-Forward Loop Triggered by the Complement Component C3 as a Potential Target in Endometriosis 69
FRI0030 Anti-TNF-α Antibody Targeted To Inflamed Synovial Tissue for The Treatment of Rheumatoid Arthritis 63
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab 63
Effects of chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles on a human/mouse model of Burkitt lymphoma 62
Complement Activation and Thrombin Generation by MBL Bound to β2-Glycoprotein I 59
The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target 50
Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination 44
The terminal complement pathway is activated in septic but not in aseptic shoulder revision arthroplasties 42
Nanoparticles-based oligonucleotides delivery in cancer: Role of zebrafish as animal model 41
High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids 39
Phage Display Technology for Human Monoclonal AntibodiesHuman Monoclonal Antibodies 38
An allosteric redox switch in domain V of β2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition 38
Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients 36
Complement system and phagocytosis in a colonial protochordate 33
Cubosomes stabilized by a polyphosphoester-analog of Pluronic F127 with reduced cytotoxicity 32
The J-elongated conformation of b2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome 32
C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. 27
Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. 22
Biological Features of Nanoparticles: Protein Corona Formation and Interaction with the Immune System 16
Hereditary deficiency of the second component of complement: Early diagnosis and 21-year follow-up of a family 16
Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies 15
Plasminogen activator-coated nanobubbles targeting cell-bound β2-glycoprotein I as a novel thrombus-specific thrombolytic strategy 6
Totale 9075
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13190
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13190
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018219 0000 00 00 46498539
2018/20191388 454929123 7293 3691 88157378227
2019/20202265 166163140350 190264 232205 19314114279
2020/20211380 183100112146 118119 92105 8212066137
2021/2022999 90747088 2169 3835 1279853236
2022/20231388 129228118234 89251 40151 148000
Totale 9075